Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CSTI 300

Next Previous
Search
Drug Profile

CSTI 300

Alternative Names: CSTI-300; SMP-100

Latest Information Update: 28 Jul 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AMRI; Celentyx
  • Developer Chengdu SciMount Pharmatech
  • Class Benzazepines; Bridged-ring heterocyclic compounds; Irritable bowel syndrome therapies; Pyrazoles; Quinuclidines; Small molecules
  • Mechanism of Action Serotonin 5-HT3 receptor partial agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Inflammatory bowel diseases

Most Recent Events

  • 28 Jul 2023 No recent reports of development identified for phase-I development in Inflammatory-bowel-diseases(In volunteers, In adults) in Australia (PO, Liquid)
  • 10 Dec 2021 Chengdu SciMount Pharmatech completes a phase I pharmacokinetic trial in healthy volunteers in Australia (PO) in December 2021 (NCT05029518)
  • 09 Sep 2021 Chengdu SciMount Pharmatech initiates enrolment in a phase I pharmacokinetic trial in healthy volunteers in Australia (PO) in September 2021 (NCT05029518)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top